TRM expressed CXCL13, the immune checkpoints LAG3, PDCD1 (PD-1), HAVCR2 (TIM-3), TIGIT, CTLA4, a regulator of tissue-residency ZF683 and markers of tumor-specific response TOX [55] and ENTPD1 (CD39), consistent with Simoni et al.’s [44] study. This evidence concerns the gene HAVCR2 and neoplasm.